Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine

Journal of Virology

Volumn 78, Issue 14, 2004, Pages 7545-7552

  García Lerma, J Gerardo ^a   MacInnes, Hamish ^a   Bennett, Diane ^a   Weinstock, Hillard ^a   Heneine, Walid ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; STAVUDINE; THYMIDINE DERIVATIVE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CONCENTRATION RESPONSE; DISEASE TRANSMISSION; DRUG RESISTANCE; GENE MUTATION; GENETIC RESISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MAJOR CLINICAL STUDY; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; UNITED STATES; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS TRANSMISSION; WILD TYPE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA; VIRUS REPLICATION; ZIDOVUDINE;

EID: 19244372885     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.14.7545-7552.2004     Document Type: Article

References (38)

1. Boden, D., A. Hurley, L. Zhang, Y. Cao, Y. Guo, E. Jones, J. Tsay, J. Ip, C. Farthing, K. Limoli, N. Parkin, and M. Markowitz. 1999. HIV-1 drug resistance in newly infected individuals. JAMA 282:1135-1141.
2. Brenner, B. G., J. P. Routy, M. Petrella, D. Moisi, M. Oliveira, M. Detorio, B. Spira, V. Essabag, B. Conway, R. Lalonde, R. P. Sekaly, and M. A. Wainberg. 2002. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J. Virol. 76:1753-1761.
3. Brodine, S. K., R. A. Shaffer, M. J. Starkey, S. A. Tasker, J. L. Gilcrest, M. K. Louder, A. Barile, T. C. VanCott, M. T. Vahey, F. E. McCutchan, D. L. Birx, D. D. Richman, and J. R. Mascola. 1999. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann. Intern. Med. 131:502-506.
4. Conlon, C. P., P. Klenerman, A. Edwards, B. A. Larder, and R. E. Phillips. 1994. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J. Infect. Dis. 169:411-415.
5. D'Aquila, R. T., V. A. Johnson, S. L. Welles, A. J. Japour, D. R. Kuritzkes, V. DeGruttola, P. S. Reichelderfer, R. W. Coombs, C. S. Crumpacker, J. O. Kahn, D. D. Richman, et al. 1995. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann. Intern. Med. 122:401-408.
6. de Ronde, A., M. van Dooren, E. de Rooij, B. van Gemen, J. Lange, and J. Goudsmit. 2000. Infection by zidovudine-resistant HIV-1 compromises the virological response to stavudine in a drug-naive patient. AIDS 14:2632-2633.
7. Deeks, S. G., T. Wrin, T. Liegler, R. Hoh, M. Hayden, J. D. Barbour, N. S. Hellmann, C. J. Petropoulos, J. M. McCune, M. K. Hellerstein, and R. M. Grant. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344:472-480.
8. de Ronde, A., M. van Dooren, L. van Der Hoek, D. Bouwhuis, E. de Rooij, B. van Gemen, R. de Boer, and J. Goudsmit. 2001. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J. Virol. 75:595-602.
9. Devereux, H. L., V. C. Emery, M. A. Johnson, and C. Loveday. 2001. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J. Med. Virol. 65:218-224.
10. Dykes, C., K. Fox, A. Lloyd, M. Chiulli, E. Morse, and L. M. Demeter. 2001. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology 285:193-203.
11. Erice, A., D. L. Mayers, D. G. Strike, K. J. Sannerud, F. E. McCutchan, K. Henry, and H. H. Balfour. 1993. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N. Engl. J. Med. 328:1163-1165.
12. García-Lerma, J. G., P.J. Gerrish, A. J. Wright, S. H. Qari, and W. Heneine. 2000. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside resistant HIV-1. J. Virol. 74:9339-9346.
13. García-Lerma, J. G., H. MacInnes, D. Bennett, P. Reid, S. Nidtha, H. Weinstock, J. Kaplan, and W. Heneine. 2003. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J. Virol. 77:5685-5693.
14. Garcia-Lerma, J. G., S. Nidtha, K. Blumoff, H. Weinstock, and W. Heneine. 2001. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc. Natl. Acad. Sci. USA 98:13907-13912.
15. Gonzales, M. J., T. D. Wu, J. Taylor, I. Belitskaya, R. Kantor, D. Israelski, S. Chou, A. R. Zolopa, W. J. Fessel, and R. W. Shafer. 2003. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 17:791-799.
16. Goudsmit, J., A, de Ronde, D. D. Ho, and A. S. Perelson. 1996. Human immunodeficiency virus fitness in vivo: calculations based on single zidovudine resistance mutation at codon 215 of reverse transcriptase. J. Virol. 70:5662-5664.
17. Grant, R. M., F. M. Hecht, M. Warmerdam, L. Liu, T. Liegler, C. J. Petropoulos, N. S. Hellmann, M. Chesney, M. P. Busch, and J. O. Kahn. 2002. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288:181-188.
18. Hecht, F. M., R. M. Grant, C. J. Petropoulos, B. Dillon, M. A. Chesney, H. Tian, N. S. Hellmann, N. I. Bandrapalli, L. Digilio, B. Branson, and J. O. Kahn. 1998. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N. Engl. J. Med. 339:307-311.
19. Hertogs, K., M. de Bethune, V. Miller, T. Ivens, P. Schel, A. van Cauwenberge, C. Van den Eynde, V. Van Gerwen, H. Azijn, M. Van Houtte, F. Peeters, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
20. Imrie, A., A. Beveridge, W. Genn, J. Vizzard, D. A. Cooper, et al. 1997. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. J. Infect. Dis. 175:1502-1506.
21. Kuritzkes, D. R. 2001. A fossil record of zidovudine resistance in transmitted isolates of HIV-1. Proc. Natl. Acad. Sci. USA 98:13485-13487.
22. Larder, B. A., P. Kellam, and S. D. Kemp. 1991. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 5:137-144.
23. Little, S. J., E. S. Daar, R. T. D'Aquila, P. H. Keiser, E. Connick, J. M. Whitcomb, N. S. Hellman, C. J. Petropoulos, L. Sutton, J. A. Pitt, E. S. Rosenberg, R. A. Koup, B. D. Walker, and D. D. Richman. 1999. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282:1142-1149.
24. Little, S. J., S. Holte, J. P. Routy, E. S. Daar, M. Markowitz, A. C. Collier, R. A. Koup, J. W. Mellors, E. Connick, B. Conway, M. Kilby, L. Wang, J. M. Whitcomb, N. S. Hellmann, and D. D. Richman. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-394.
25. Lorenzi, P., M. Opravil, B. Hirschel, J. P. Chave, H. J. Furrer, H. Sax, T. V. Perneger, L. Perrin, L. Kaiser, and S. Yerly. 1999. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS 13:F17-F21.
26. Masquelier, B., P. E. Lemoigne, I. Pellegrin, D. Douard, B. Sandler, and H. J. A. Fleury. 1993. Primary infection with zidovudine-resistant HIV-1. N. Engl. J. Med. 329:1123-1124.
27. Nijhuis, M., S. Deeks, and C. Boucher. 2001. Implications of antiretroviral drug resistance on viral fitness. Curr. Opin. Infect. Dis. 14:23-28.
28. Petropoulos, C. J., N. T. Parkin, K. L. Limoni, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, and J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
29. Reed, L. J., and H. Muench. 1938. A simple method for estimating fifty percent end points. Am. J. Hyg. 27:493-497.
30. Schmit, J. C., J. Cogniaux, P. Hermans, C. Van Vaeck, S. Sprecher, B. Van Remoortel, M. Witvrouw, J. Balzarini, J. Desmyter, E. de Clercq, and A. M. Vandamme. 1996. Multiple drug resistance to nucleoside analogs and non-nucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J. Infect. Dis. 174:962-968.
31. Taylor, S., P. Cane, S. Hue, L. Xu, T. Wrin, Y. Lie, N. Hellmann, C. Petropoulos, J. Workman, D. Ratcliffe, B. Choudhury, and D. Pillay. 2003. Identification of a transmission chain of HIV type 1 containing drug resistance-associated mutations. AIDS Res. Hum. Retrovir. 19:353-361.
32. Veenstra, J., R. Schuurman, M. Cornelissen, A. B. van't Wout, C. A. Boucher, H. Schuitemaker, J. Goudsmit, and R. A. Coutinho. 1995. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. Clin. Infect. Dis. 21:556-560.
33. Violin, M., A. Cozzi-Lepri, R., Velleca, A. Vincenti, S. D'Elia, F. Chiodo, F. Ghinelli, A. Bertoli, A. d'Arminio Monforte, C. F. Perno, M. Moroni, and C. Balotta. 2004. Risk of virological failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS. 18:227-235.
34. Weinstock, H., R. Respess, W. Heneine, C. J. Petropoulos, N. S. Hellmann, C. C. Luo, C. P. Pau, T. Woods, M. Gwinn, and J. Kaplan. 2000. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998. J. Infect. Dis. 182:330-333.
35. Weinstock, H., I. Zaidi, W. Heneine, D. Bennett, J. G. Garcia-Lerma, J. M. Douglas, M. LaLota, G. Dickinson, S. Schwarcz, L. Torian, D. Wendell, S. Paul, G. Goza, J. Ruiz, B. Boyette, and J. E. Kaplan. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1 infected persons in 10 U.S. cities. J. Infect. Dis., in press.
36. Yerly, S., L. Kaiser, E. Race, J. P. Bru, F. Clavel, and L. Perrin. 1999. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 354:729-733.
37. Yerly, S., A. Rakik, S. K. De Loes, B. Hirschel, D. Descamps, F. Brun-Vezinet, and L. Perrin. 1998. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J. Virol. 72:3520-3523.
38. Zolopa, A. R., R. W. Shafer, A. Warford, J. G. Montoya, P. Hsu, D. Katzenstein, T. C. Merigan, and B. Efron. 1999. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann. Intern. Med. 131:813-821.